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Abstract. The CUB and sushi multiple domains 1 (CSMD1) 
gene maps to chromosome 8p23, a region deleted in many 
cancers. Loss of CSMD1 expression is associated with poor 
prognosis in breast cancer suggesting that it acts as a tumour 
suppressor in this cancer. However, the function of CSMD1 is 
largely unknown. Herein, we investigated CSMD1 functions in 
cell line models. CSMD1 expression was suppressed in MCF10A 
and LNCaP cells using short hairpin RNA. Functional assays 
were performed focusing on the ‘normal’ MCF10A cell line. 
Suppression of CSMD1 significantly increased the proliferation, 
cell migration and invasiveness of MCF10A cells compared to 
shcontrols. shCSMD1 cells also showed significantly reduced 
adhesion to Matrigel and fibronectin. In a three-dimensional 
Matrigel model of MCF10A cells, reduced CSMD1 expression 
resulted in the development of larger and more poorly differenti-
ated breast acini-like structures that displayed impaired lumen 
formation. Loss of CSMD1 expression disrupts a model of 
mammary duct formation while enhancing proliferation, migra-
tion and invasion. Our data suggest that CSMD1 is involved in 
the suppression of a transformed phenotype.
Introduction
CUB and sushi multiple domains-1 (CSMD1) is a very large 
gene which contains 71 exons that span over 2 Mb of genomic 
DNA on chromosome 8p23 (1). Multiple splice variants exist 
for CSMD1 and these encode proteins of varying length. The 
largest transcript is 14.3 kb long and this encodes a 3,565 amino 
acid protein (1). The full-length protein is a membrane 
protein with an extracellular region containing 14 CUB and 
28 sushi domains, a single transmembrane domain and a short 
cytoplasmic domain that contains a putative tyrosine phos-
phorylation site. CSMD1 belongs to the CSMD gene family 
whose members also include the structurally similar proteins 
CSMD2 and CSMD3 (1-3). The function of CSMD1 is largely 
unknown. Although CSMD1 has been shown to inhibit C3 
deposition onto the surface of cells leading to the inhibition 
of the classical complement pathway (4,5). The structure 
of CSMD1 predicts that CSMD1 is a receptor for unknown 
ligand(s) and is involved in signal transduction (1).
CSMD1 is believed to act as a tumour suppressor based 
on a number of observations. CSMD1 is located on chromo-
some 8p23, a region that is frequently deleted in different 
types of cancer (1,6-10). In addition, reduced CSMD1 
mRNA and protein expression has been observed in different 
cancers (11-17). An array comparative genomic hybridization 
study revealed a high rate of loss of 8p23.2 containing the 
CSMD1 gene in advanced prostrate cancer samples. A further 
small real-time PCR study identified a decrease in CSMD1 
mRNA levels in higher stage prostrate cancer samples (11). 
Similarly reduced CSMD1 expression at the mRNA level has 
been identified in colorectal cancer associated with reduced 
patient survival (12). Furthermore, somatic mutations were 
detected in CSMD1 in 11% (6/54) of colorectal cancer patients 
along side DNA methylation and allele loss, predominantly 
in early onset patients (13). Previously, we demonstrated in a 
large series of breast cancers that 79/275 (28.7%) had reduced 
CSMD1 protein expression. Low CSMD1 expression was 
significantly associated with high tumour grade (p=0.003) 
and decreased overall survival (p=0.018). Importantly multi-
variate analysis showed that CSMD1 was also an independent 
predictor of overall survival (p=0.03) (14).
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Recently, in vivo and in vitro studies using the A375 
melanoma cell line have also shown CSMD1 functions as a 
tumour suppressor gene (15). Overexpression of CSMD1 in 
melanoma cells resulted in reduced migration and prolifera-
tion and induced apoptosis. In addition, xenografted tumours 
expressing CSMD1 resulted in reduction of tumour weight 
and size (15) Of note, reduced mRNA CSMD1 expression 
has been identified in glioblastoma stem cells compared to 
neural stem cells (16). Downregulation of CSMD1 was linked 
to up regulation of the microRNAs miR-10a and miRNA-
10b which formed an inhibitory complex with the 3'UTR of 
CSMD1 (16). Similarly high levels of miRNA-10b associated 
with low levels of CSMD1 expression were identified in HepG2 
hepatocellular carcinoma cells (17).
In this study, we investigated the consequences of loss 
of CSMD1 expression on cell behaviour. We used a three-
dimensional (3D) MCF10A/Matrigel model to study the role of 
CSMD1 in mammary cell differentiation. This culture system 
has been recently used to address fundamental questions 
about processes that disrupt epithelial architecture. It provides 
culture conditions that allow mammary epithelial cells to 
respond to extracellular matrix (ECM) signals that impact 
upon proliferation, differentiation or death (18,19). We found 
that loss of CSMD1 expression enhanced cell proliferation, 
migration and invasion. Furthermore, it reduced cell-adhesion. 
Moreover, in the 3D culture system, reduced CSMD1 expres-
sion disrupted the morphogenesis of epithelial structures and 
impaired lumen formation.
Materials and methods
Cell culture. MCF10A cells were obtained from the American 
Type Culture Collection and LNCaP cells were obtained 
from European Collection of Cell Cultures. MCF10A was 
cultured in DMEM-F12 medium (Invitrogen, Paisley, UK) 
as previously described (18). LNCaP cells were cultured in 
RPMI (Invitrogen) containing 10% foetal calf serum (FCS) 
(Sigma-Aldrich, Dorset, UK). All cell lines were maintained 
at 37˚C and 5% CO2 in the tissue culture incubator and were 
routinely tested using MycoAlert® Mycoplasma detection 
assay (Lonza, Walkersville, MD, USA).
Generation of shCSMD1 stable cell lines. CSMD1 shRNA 
pRS vectors (HuSH™, OriGene, Rockville, MD, USA) were 
transformed into NEB 5-α competent E. coli (New England 
BioLabs, Ipswich, MA, USA) and grown in L broth containing 
50 µg/ml ampilicillin (Sigma-Aldrich). Sequences of CSMD1 
shRNA constructs and their cognate CSMD1 mRNA regions 
are shown in Table I. For each cell line, 1x106 cells/ml were 
transfected with either shCSMD1 or shcontrol constructs 
using Lipofectamine™ 2000 (Invitrogen). Cells were then 
grown in media that contained the appropriate dose (0.5 µg/ml, 
MCF10A; 0.01 µg/ml, LNCaP) of puromycin (Sigma-Aldrich) 
for 2 weeks. Single cell colonies were selected by serial dilu-
tions in 96-well plates.
Reverse transcriptase polymerase chain reaction (RT-PCR). 
RNA was extracted from cells using TRIzol (Invitrogen). 
First strand cDNA synthesis was then performed using 
ThermoScript (Invitrogen) and random hexamers (Promega, 
Southampton, UK) following the manufacturer's instructions. 
To test the specificity of shRNA constructs, CSMD3 was 
amplified. PCR reactions were performed using HotStarTaq 
(Qiagen, West Sussex, UK) following the manufacturer's 
instructions. The final extension step was for 10 min at 68˚C. 
Annealing temperature of the CSMD3 primers was 52˚C and 
50˚C for the housekeeping gene RPLP0. PCR products were 
analysed in 1.5% agarose gel containing ethidium bromide. 
For primer sequences of CSMD3 and the housekeeping gene 
RPLP0, see Table II.
Quantitative real-time PCR reactions (qRT-PCR). CSMD1 and 
RPLP0 expression levels were investigated in all shCSMD1 
and shcontrol clones using the relative standard curve method. 
TaqMan reactions, using sensiMix dT master mix (Quantace, 
London, UK), were performed in duplicates and run on 
an ABI7500 (Applied Biosystems, Warrington, UK). For 
sequences of primers and probes, see Table III.
Immunohistochemistry (IHC). IHC was performed to confirm 
the knockdown of CSMD1 protein expression in shRNA clones. 
Cells were pelleted, formalin fixed and paraffin-embedded 
and CSMD1 was stained using chicken anti-CSMD1 antibody 
at a 1:3000 dilution, as previously described (14). Negative 
controls, in which the pre-immune serum was applied, and 
positive controls of normal breast tissue were included in each 
batch of IHC.
Cell viability. Cell viability was evaluated using the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay. Cells (1x104 cells/ml) were incubated with MTT solu-
tion (1 mg/ml) (Sigma-Aldrich) for 3-4 h at 37˚C. Crystals 
were dissolved in propan-1-ol and their optical densities (OD) 
were quantified at 570 nm (Opsys MR Plate reader; Dynex 
Technologies, West Sussex, UK).
Wound healing assay. Confluent monolayers were incubated 
in mitomycin C (10 µg/ml) (ICN Biomedicals, Costa Mesa, 
CA, USA) for 2 h at 37˚C to inhibit cell division. Wounds 
were introduced into the monolayer by scratching with a P200 
micropipette tip. Wound closure was followed for 96 h and 
phase contrast images were captured using an Olympus digital 
still camera attached to an Olympus inverted microscope with 
a 4X objective lens. The wound area was imaged using ImageJ 
and expressed as a percentage of the wound area covered at 
each time point relative to the surface area of the wound at 
time zero.
Transwell invasion assay. Invasion assays were carried out as 
previously described (20). The upper sides of 12-well format 
transwell inserts (BD Biosciences, Franklin Lakes, NJ, USA) 
were coated with Matrigel at a 1:10 dilution in serum-free 
medium (SFM). The undersides of the inserts were coated with 
fibronectin (10 µg/ml in PBS). Medium containing FCS (1 ml) 
was added to the base of each well. Cells at 5x104 cells/ml in 
SFM were placed on the top of inserts, for 16 h. Invasive cells 
that penetrated through to the underside of the inserts were 
identified by fixation in 4% paraformaldehyde and staining 
with crystal violet. Cells were then destained using 2% SDS 
and the OD was measured using the Opsys MR Plate reader at 
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570 nm. The percentage of invasion was calculated indepen-
dently using the following equation: Cell invasion (%) = OD 
of cells in the bottom/OD of cells in the bottom + OD of cells 
in the top.
Cell adhesion assays. Plates (96-well) were coated with 
fibronectin (10 µg/ml in PBS) or Matrigel (20 µg/ml in SFM). 
Non-specific adhesion sites were blocked by pre-incubation 
in 0.5% bovine serum albumin in DMEM or RPMI. Cells at 
4x105 cells/ml were pipetted onto the coated plates at 37˚C 
and allowed to attach for 30 min or 2 h. Following this, unat-
tached cells were aspirated and the remaining attached cells 
were fixed in 4% paraformaldehyde and stained with crystal 
violet. Cells were then destained using 2% SDS and OD was 
measured using the Opsys MR Plate reader at 570 nm.
MCF10A Matrigel assay. 3D Matrigel cultures of MCF10A 
cells were performed as previously described (18). Briefly, 
8-well glass slides (Nunc™; Nalge Nunc International 
Corp., Rochester, NY, USA) were coated with growth factor 
reduced Matrigel (BD Biosciences). shcontrol or shCSMD1 
MCF10A cells (5000 cells/ml in 2% Matrigel assay medium) 
were seeded onto the slides and incubated at 37˚C for up to 
26 days. Cells were fed every 3-4 days with 2% Matrigel 
assay medium.
Fluorescence analysis and image acquisition. Fluorescent 
staining of acinar structures was performed as previously 
described (18). Phalloidin (Invitrogen), was used as a cytoskel-
etal marker at a 1:50 dilution. Rabbit polyclonal active caspase-3 
antibody (Abcam, Cambridge, UK) was used as an apoptotic 
marker at a 1:100 dilution. Fluorescence staining was imaged 
using a Nikon confocal microscope (Nikon Eclipse TE2000-E; 
Nikon UK, Kingston Upon Thames, UK). Images of acinar 
structures were captured by serial confocal sectioning and 
viewed using confocal software. Phase contrast images were 
captured using an Olympus digital still camera attached to an 
Olympus inverted microscope (Olympus CKX41). All images 
were converted to TIFF format and figures were assembled 
and annotated using Adobe Photoshop 7.0®.
Statistical analysis. Initially the distribution of the data from 
all the functional assays except wound healing assay was tested 
using Shapiro-Wilk or Kolmogorov-Smirnov tests. When the 
data were normally distributed, a t-test was used to compare 
between means. A Mann-Whitney U test (non-parametric) was 
used when the data were not normally distributed. All tests 
were 2-sided and performed using SPSS software version 15. 
A p-value ≤0.05 was considered to be statistically significant.
Results
Generation of shCSMD1 stable cell lines. To help determine 
the function of CSMD1, shRNA gene silencing methodology 
was used to create stable cell lines with suppressed CSMD1 
expression. Two different cell lines were analysed: MCF10A 
(normal breast) and LNCaP (prostate). Single cell colonies 
were selected from all cell lines and the mRNA expression 
level of CSMD1 was investigated using qRT-PCR. Colonies 
that showed the best level of mRNA knockdown were chosen 
for subsequent experiments. Two separate shCSMD1 cell lines 
were generated from the MCF10A cells (termed clone 1 and 2) 
and a single cell line was generated from the LNCaP cells. 
MCF10A shCSMD1 clones 1 and 2 showed a 66% (SD±8.9%) 
and 66.9% (SD±12%) reduction in CSMD1 mRNA expression, 
respectively, when compared to shcontrol cells. The LNCaP 
cell line showed a 62% (SD±12%) CSMD1 mRNA knock-
down, relative to shcontrols (Fig. 1A).
To confirm these levels of knockdown at the protein level, 
CSMD1 protein expression was investigated using IHC since 
at the time a CSMD1 antibody suitable for westerns was not 
available. MCF10A shCSMD1 colonies showed lower CSMD1 
protein expression compared to the shcontrol. However, unex-
pectedly, the LNCaP shCSMD1 cells did not show a reduced 
level of protein expression compared to shcontrols cells in 
contrast to the high reduction in CSMD1 mRNA expression 
observed by qRT-PCR (Fig. 1B).
To test the specificity of the shCSMD1 constructs the 
expression of CSMD3 mRNA was investigated using RT-PCR. 
Since normally none of the tested cell lines express CSMD2 
its expression was not tested. The shCSMD1 constructs did 
not affect the expression pattern of CSMD3 in either of the 
cell lines examined. Moreover, the shcontrol plasmids had no 
effect on the expression pattern of CSMD3 (Fig. 1C).
Downregulation of CSMD1 disrupts cell morphology. To 
investigate the morphology of the shCSMD1 cells, the F-actin 
Table I. shCSMD1 construct sequences.
Construct Sequence The cognate CSMD1 mRNA regions
1 CCA CAG GCA GAA ATG CTT ACT GAG ATG A 5234-5263 bp
2 GAG GAC ATC CAC AGC ACC TTC AAC TCA CT 2505-2534 bp
3 GGC TTC CTC ATC CAC TAT GAG AGT GTG AC 1013-1042 bp
4 CAT AGC CAT ACC TCT GAT GGA CAA GCA GT 8929-8958 bp
Table II. RT-PCR primer sequences.
Gene Primers 5'-3'
CSMD3 Forward: AGTAGTTCTGTAGCCATTGC
 Reverse: TGGGATCAAATCGTACCGCC
RPLPO Forward: ACATGCTCAACATCTCCC
 Reverse: TTCAACCTTAGCTGGGG
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stain Phalloidin was used to examine the cells. Staining 
revealed that in all lines examined, loss of CSMD1 expression 
resulted in misshapen cells that tended to grow individually. In 
contrast, shcontrol cells mainly grew as colonies. In MCF10A, 
many shCSMD1 cells possessed lamellipodia-like protrusions 
suggestive of a motile phenotype (Fig. 2, arrow). LNCaP 
shCSMD1 cells displayed very long filopodia-like protrusions 
(Fig. 2, arrows). In all cases these features were not observed 
in the appropriate shcontrol cell lines.
Effect of CSMD1 suppression on cell proliferation, migration 
and invasion. Having shown that CSMD1 silencing affected 
cell morphology, using MCF10A cells as a model we focused 
on understanding its functional effects by investigating a 
number of important cellular processes. Since minimal knock-
down at the protein level was observed in the LNCap cell line 
further functional work was not performed in these cells. Cell 
proliferation was assayed using the MTT protocol. Silencing 
CSMD1 expression did not significantly affect cell prolifera-
tion until 72 h post-plating when increases of 34% (SD±4%, 
p=0.003) and 56% (SD±3.3%, p=0.001) were observed in 
MCF10A shCSMD1 clones 1 and 2 (Fig. 3).
Since the morphology of the MCF10A shCSMD1 cells 
suggested that they were more motile than their shcontrol 
Figure 1. Confirmation of CSMD1 expression knockdown. (A) qRT-PCR, 
using the relative standard curve method confirmed the shRNA vectors 
reduced CSMD1 mRNA expression. MCF10A shCSMD1 clones 1 and 2, 
exhibited 66 and 67% reduction in CSMD1 expression, respectively. While, 
the knockdown efficiency in LNCaP was 62%. The percentages of CSMD1 
expression (relative to shcontrols) are presented as means ± SD of at least 
3 independent experiments. (B) IHC using chicken anti-CSMD1 antibody 
on formalin-fixed paraffin-embedded cells revealed that shCSMD1cells 
exhibit lower CSMD1 protein expression levels compared to shcontrols. 
Magnification, x100. (C) Confirmation of specificity of shRNA CSMD1 vec-
tors. RT-PCR for CSMD3 in shCSMD1 cells did not detect any changes in 
the expression of this genes or the housekeeping gene RPLPO. Foetal brain 
cDNA was used as a positive control and water as a negative control. M, size 
standard marker.
Figure 2. Loss of CSMD1 expression disrupts cell morphology. Phalloidin 
staining revealed that, in all cell lines, reduced CSMD1 expression resulted 
in misshapen cells lacking cell-cell contacts. Abundant MCF10A shCSMD1 
cells are migrating with lamellipodia-like protrusions (arrow head). LNCaP 
shCSMD1 cells exhibit long filopodia-like protrusions (arrows). Nuclei are 
stained with DAPI. Magnification, x40; scale bar, 50 µm.
Figure 3. Loss of CSMD1 expression increases cell proliferation. MTT assays 
revealed that silencing of CSMD1 expression increased proliferation rates 
of MCF10A, after 72 h, shCSMD1 clones 1 and 2 showed 34% (*p<0.003) 
and 56% (**p<0.001) increase in proliferation. The percentages of cell pro-
liferation, relative to shcontrols, are presented as the mean ± SD of at least 
3 independent experiments) after 24 h, respectively.
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counterparts (Fig. 2), we next investigated the role of CSMD1 
in cell migration. Wound healing assays were performed after 
inhibiting MCF10A proliferation by treating cells with mito-
mycin C prior to the experiment. In the shcontrol cells 14.15% 
(SD±3.6%) and 31.55% (SD±4.3%) of the wound were covered 
during the first 16 h and 24 h after wounding respectively. In 
the shCSMD1 clones 1 and 2, 37.02% (SD±8.5%, p=0.07) 
and 56.15% (SD±7.1%, p=0.018) of the wound were covered 
during the first 16 h. Moreover, after 24 h, cells in shCSMD1 
clones 1 and 2 covered 69.9% (SD±6.6%, p=0.02) and 88.2% 
(SD±0.9%, p=0.003) of the wound (Fig. 4A and B), confirming 
that suppression of CSMD1 expression promotes a more motile 
phenotype in MCF10A cells.
Since loss of CSMD1 promoted cell migration, we next 
studied its role in cell invasion. At 16 h after plating, suppres-
sion of CSMD1 expression resulted in 33% (SD±3%, p<0.001) 
Table III. qRT-PCR primer and probe sequences.
Gene Primers Probe
CSMD1 Forward: TTCCAGATTTTTATCCAAACTCTCTAA CACGTGGACCATTGAAGTGTCTCATGG
 Reverse: GTGTGAAAGATCATTTGAACTCCTTT
RPLPO Forward: AGATGCAGCAGATCCGCAT AGGCTGTGGTGCTGATGGGCAAGAAC
 Reverse: ATATGAGGAGCAGTTTCTCCAG
Figure 4. Loss of CSMD1 expression increases cell migration and invasion. (A) Wound healing assays, after inhibiting cell proliferation by mitomycin C, 
revealed that loss of CSMD1 expression enhanced migration of MCF10A cells. Images were taken, using phase contrast microscopy every 8 h. Magnification, x4; 
scale bar, 500 µm. (B) In the MCF10A shcontrol cells 14.15 and 31.55% of the wound were covered after 16 and 24 h, respectively. In the MCF10A shCSMD1 
clones 1 and 2, 37.02% (p=0.07) and 56.15% (*p=0.018) of the wound were covered after 16 h and 69.9% (**p=0.02) and 88.2% (***p=0.003) after 24 h, respec-
tively. The percentages of the surface area of the wound covered relative to time point zero, are presented as the mean ± SD of two independent experiments. 
(C) MCF10A shCSMD1 clones 1 and 2 showed 33% (*p<0.001) and 26% (**p<0.001) increase in invasion, respectively. The percentages of cell invasion, relative 
to shcontrols, are presented as the mean ± SD of at least 3 independent experiments.
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and 26% (SD±6%, p<0.001) increases in cell invasion of 
MCF10A shCSMD1 clones 1 and 2, respectively, compared to 
shcontrol (Fig. 4C).
Effect of CSMD1 suppression on cell matrix adhesion. 
Shared homology with Cub domain containing protein 1 
(CDCP1), which is involved in cell-matrix interactions (21,22), 
suggested that CSMD1 could play a role in cell adhesion. To 
examine this possibility adhesion assays using Matrigel and 
fibronectin were performed 30 min and 2 h after cell plating. 
Loss of CSMD1 expression caused ~34% (SD±8.5%, p=0.001) 
and ~17% (SD±15%, p=0.06) decreases in the adhesion of 
MCF10A shCSMD1 clones 1 and 2 to fibronectin after 30 min, 
compared to shcontrol. After 2 h, this difference had increased 
to ~36% (SD±10%, p=0.01) and ~40% (SD±15%, p=0.004) 
respectively (Fig. 5A). Following CSMD1 silencing, adhesion 
of MCF10A shCSMD1 clones 1 and 2 to Matrigel decreased by 
20% (SD±13.5%, p=0.02) and 16% (SD±8.5%, p=0.05) after 
30 min compared to shcontrol. Strikingly, 2 h after plating 
these differences had increased to 44% (SD±7.6%, p=0.0006) 
and ~42% (SD±9.6%, p=0.001) (Fig. 5B).
Loss of CSMD1 expression disrupts acini formation. We have 
previously observed that CSMD1 is highly expressed in well-
differentiated areas of breast cancer samples, suggesting that 
CSMD1 might play a role in mammary duct formation (14). 
To examine this further, an MCF10A 3D Matrigel model was 
established and the effects of CSMD1 knockdown on the 
morphogenesis of mammary acini were investigated. Loss of 
CSMD1 expression resulted in a larger number of acini and 
larger areas of flat cells (Fig. 6A, arrows). Acini in 3 fields 
from 3-5 independent experiments were counted and averaged 
every 2-4 days. There was a statistically significant increase in 
the average number of shCSMD1 acini compared to shcontrol 
at all time points (p<0.05) (Fig. 6B).
Phalloidin staining and confocal microscopy revealed that 
shCSMD1 acini were irregular in shape and heterogeneous in 
size (Fig. 7A). The diameter of each acinus was measured and 
the mean diameter of acini from shcontrol cells determined 
(85 µm). This was then used as a cut-off to distinguish between 
large and small acini. Noteworthy, the proportion of large acini 
in MCF10A shCSMD1 clones 1 and 2 were 33% (SD±21%, 
p=0.1) and 43% (SD±15%, p=0.03) higher than in the shcontrol 
cell line (Fig. 7B). Furthermore, confocal imaging revealed 
that in shCSMD1 clones 1 and 2, respectively, 55% (SD±9.8%, 
p=0.045) and 90% (SD±8%, p=0.008) of acini failed to form a 
lumen compared to shcontrol cells (Fig. 7C).
In this model system lumen formation depends on apop-
tosis, raising the possibility that a failure to generate acini 
with a lumen might be due to differences in developmentally 
regulated programmed cell death in cells where CSMD1 
Figure 5. Loss of CSMD1 expression decreases cell adhesion to the ECM. 
Adhesion assays revealed that MCF10A shCSMD1 cell lines exhibit less 
adhesion to fibronectin (A) and Matrigel (B) than their shcontrols, at 30 min 
and 2 h post-cell plating. The percentages of adhesion, relative to shcontrols 
are presented as means ± SD of at least 3 independent experiments. Asterisks 
(*) denote statistically significant differences between shcontrol cells and 
shCSMD1 clones (*p<0.05).
Figure 6. Reduced CSMD1 expression increases acini number and increases 
areas of flat cells in the MCF10A 3D model. (A) The morphogenesis of 
MCF10A acini was monitored and images were captured every 2-4 days, 
using phase contrast microscopy. Reduced CSMD1 expression caused an 
increase in the number of acini compared to shcontrol acini. shCSMD1 
cells exhibited larger areas of flat cells compared to shcontrol cells (arrows). 
Magnification, x4; scale bar, 500 µm. (B) The numbers of MCF10A 
shCSMD1 acini are presented as the mean ± SD of 3 fields from 3-5 inde-
pendent experiments. Asterisks (*) denote statistically significant differences 
between shcontrol cells and shCSMD1 clones (*p<0.05).
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expression is inhibited. To test this, acini at day 12 (before the 
completion of lumen formation in shcontrol cells) and day 26 
were stained with antibodies specific for active caspase-3. At 
day 26, lumens of shcontrol acini showed very weak staining 
compared to shCSMD1 lumens (Fig. 7A, arrows). However, 
at day 12, shcontrol acini showed strong staining of active 
caspase-3 (Fig. 7D). These observations confirm that during 
normal acinar development in this model system a lumen is 
generated by temporally coordinated apoptotic processes. 
Apoptosis is then severely suppressed or absent after the 
completion of lumen in shcontrol acini. In contrast, because 
shCSMD1 acini failed to form a lumen, apoptotic processes 
remain active until day 26.
Discussion
CSMD1 encodes a transmembrane protein and is thought to 
function as a tumour suppressor. The function of CSMD1 is 
largely unknown. However, it is suggested to be a receptor 
or co-receptor involved in signal transduction (1). Herein, 
we investigated the biological consequences of loss of 
CSMD1 expression in cell line models. CSMD1 expression 
was suppressed in the cell lines MCF10A and LNCaP, using 
CSMD1 shRNA pRS vectors. The specificity of these vectors 
was validated, demonstrating that CSMD3 expression was not 
affected. This is an important consideration since it is possible 
that functional overlap between the CSMD proteins may 
modify the phenotype resulting from the loss of any one of 
them in tumours (1).
In both cell lines examined, downregulation of CSMD1 
expression caused cell dissociation reflecting a more motile 
phenotype with enhanced formation of lamellipodia and 
filopodia-like protrusions. Formation of such structures is 
an indicator of extensive actin polymerisation (23). Previous 
studies have revealed that the rat ortholog of CSMD1 colocal-
izes with F-actin (4,24). Thus CSMD1 may have an inhibitory 
effect on actin assembly or the signalling processes that impact 
upon the regulation of this process (25).
Further functional assays were focused on the MCF10A 
cell line which demonstrated high CSMD1 protein knockdown 
by IHC compared to the lower levels of protein knockdown 
observed in the LNCaP cells. Loss of CSMD1 expression 
increased cell proliferation. This agrees with studies that 
showed expression of the rat ortholog of CSMD1 is low in 
brain regions exhibiting high levels of cell proliferation (4). 
Similarly, a recent study has demonstrated that increasing 
miRNA-10b expression in HepG2 hepatocellular carcinoma 
cells resulted in decreased CSMD1 expression and increased 
proliferation (17). Our results also complement a study where 
increased expression of CSMD1 in A375 melanoma cells 
reduced proliferation (15). The inhibitory role of CSMD1 
on cell proliferation is also in line with a potential role in 
Figure 7. Silencing CSMD1 expression disrupts mammary acini morphology and inhibits lumen formation in the MCF10A 3D model. (A) Acini, at day 26, 
stained with DAPI (blue), phalloidin (red), and active caspase-3 antibody (green). Magnification, x40; scale bar, 50 µm. shCSMD1 acini are irregular in shape 
and heterogeneous in size with no lumen. shcontrol acini showed weak staining for active caspase-3, while, lumens of shCSMD1 acini exhibit strong staining 
(arrows). (B) The percentages of large acini, relative to shcontrol, are presented as the mean ± SD of at least 3 independent experiments. Reduced CSMD1 
expression resulted in 33% (p=0.1) and 43% (*p=0.03) increase in the percentage of large acini in MCF10A shCSMD1 clones 1 and 2, respectively. (C) The 
percentages of lumen forming acini, relative to shcontrol, are presented as the mean ± SD of at least 3 independent experiments. Reduced CSMD1 expression 
resulted in 55% (**p=0.045) and 90% (***p=0.008) decrease in the percentage of lumen forming acini in MCF10A shCSMD1 clones 1 and clone 2, respectively. 
(D) shcontrol acini, at day 12, stained with DAPI (blue) and active caspase-3 antibody (green). Magnification, x40; scale bar, 50 µm.
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cell differentiation, where CSMD1 enhances mammary duct 
formation. In normal development, growth arrest precedes 
differentiation and defects in the processes that control differen-
tiation and proliferation are associated with carcinogenesis (26).
Reduced CSMD1 expression also enhanced cell migration 
in MCF10A CSMD1 knockdown cells. A similar increase in 
migration was identified in HepG2 hepatocellular carcinoma 
cells with increased miRNA-10b expression resulting in 
reduced CSMD1 expression (17). These findings also comple-
ment work in A375 melanoma cells where overexpression of 
CSMD1 reduced cell migration compared to control cells (15). 
Migration is a process of 4 steps; cell polarization, formation 
of lamellipodia, focal adhesions, and detachment of the cell 
rear as the cell front advances. Our data suggest that CSMD1 
normally suppresses the formation of cellular morphologies 
associated with motility (such as lamellipodia). At focal adhe-
sions integrins interact with actin providing a link between 
the cytoskeleton and the extracellular environment (27). The 
co-localisation of CSMD with both α3-integrin and F-actin 
suggests that CSMD1 may also be involved in the forma-
tion of these structures (24). Previous work has shown that 
the strength of focal adhesions determines the translocation 
velocity of the cell, with maximal velocities reached at inter-
mediate adhesion strengths (23,28-31). This might suggest 
that the presence of CSMD1 strengthens focal adhesions, 
which in turn impairs migration.
Since downregulation of CSMD1 expression affected 
cell migration, further investigations into whether changes 
in migration were concomitant with changes in cell invasion 
were undertaken by performing invasion assays using the 
shCSMD1 stable cell lines. Knock-down of CSMD1 expres-
sion significantly enhanced cell invasion of MCF10A cells. 
The inhibitory effect of CSMD1 on cell invasion agrees with 
work in HepG2 hepatocellular carcinomas cells where reduced 
expression of CSMD1 due to upregulation of miRNA-10b 
caused increased invasion (17). This study provides evidence 
of a role for CSMD1 in cell migration and invasion. However, 
the mechanisms underlying these roles have not been inves-
tigated. Together with its effects on cell morphology, it is 
interesting to speculate that the role of CSMD1 in migra-
tion and invasion is through its ability to modulate the cell 
cytoskeleton. This would be in agreement with a study by 
Tang et al in melanoma cells which demonstrated CSMD1 
interacts with Smad3, activates Smad1, Smad2 and Smad3 
and increase the expression of Smad4 (15). Smad3 has been 
shown to activate Rho signalling and cytoskeletal reorganisa-
tion (32).
Downregulation of CSMD1 expression in MCF10A cells 
decreased adhesion to Matrigel and fibronectin. The stimula-
tory role of CSMD1 in cell-matrix adhesion is consistent with 
the effects of other structurally similar proteins such as neuro-
pilin-1 (33), bone morphogenetic protein 1 and TNF-stimulating 
gene 6 (34,35) in this process.
In the 3D MCF10A model of duct formation, loss of 
CSMD1 expression resulted in a larger number of acini and an 
increase in the proportion of large acini. This may be due to 
the inhibitory effect of CSMD1 on cell proliferation. Moreover, 
shCSMD1 acini are irregular in shape, which may be attributed 
to the effect of CSMD1 on the morphology of individual cells. 
This finding is similar to a study that demonstrated distorted 
MCF10A 3D structures as a result of overexpressed Akt or 
reduced expression of PDLIM2 (36,37).
Notably, a higher proportion of shCSMD1 acini failed to 
form a lumen. A filled in lumen is a hallmark feature of breast 
cancer/ductal carcinoma in situ. In breast development apop-
tosis plays a well-established role in lumen formation (38,39). 
The MCF10A 3D model has been used extensively to inves-
tigate lumen formation in vitro and numerous studies have 
clearly demonstrated that MCF10A 3D acini failure to form 
a lumen is due to increased cell proliferation combined 
with inhibition of apoptosis (18,36,40-42). In our model we 
show that this appears to be the case as caspase-3 activity 
is observed in both shCSMD1 and shcontrol acini lumen at 
day 12. However, whereas in the shcontrol cells the expres-
sion of caspase-3 is reduced after the formation of the lumen, 
in the shCSMD1 acini caspase-3 expression is still strong and 
lumen formation was incomplete. It maybe that this is due 
to the increase in cell proliferation observed in cells with 
reduced CSMD1 expression. This idea agrees with studies 
suggesting that the maintenance of acinar architecture 
relies on the ability of increased cell death to counterbal-
ance aberrant proliferation (18,36,40-42). Contrasting 
results were shown in a recent study in melanoma cell where 
CSMD1 overexpression resulted in reduced proliferation and 
increased apoptosis (15).
In future studies, it would be interesting to investigate 
mammary gland morphogenesis using an available CSMD1 
knockout mouse model (43). Whole mounts of mouse fat pads 
would be prepared at 1, 14, 21, 28, 35 days after parturition 
and the ductal network and terminal buds compared between 
Csmd1 (-/-) and wild type (+/+) litter mates. IHC staining 
would also be performed for the proliferation marker Ki67 and 
apoptosis marker active caspase-3 to identify a potential regu-
latory imbalance between the two processes during mammary 
morphogenesis. Future studies would also address a limita-
tion of the current study where CSMD1 protein knockdown 
was detected by IHC. Further experiments would involve the 
validation of the MCF10A knockdown cell lines by western 
blot using the newly available anti-CSMD1 antibody ab166908 
from Abcam.
The effects of suppressing CSMD1 expression in our cell 
culture models suggest that CSMD1 may achieve its widespread 
effects on cell behaviour by playing a role in regulating cell 
morphology. Disruption of cell morphology affects processes 
as disparate as cell adhesion, proliferation, differentiation 
and motility (44-46). Cell morphology is mainly regulated by 
the actin cytoskeleton and CSMD1 has a potential role as a 
regulator for actin polymerisation via its potential interaction 
with F-actin. Furthermore, the broad effects of CSMD1 on cell 
functions may be due to its role in cell-ECM adhesion and 
its potential interaction with α3-integrin, which have similarly 
broad effects on the regulation of actin polymerization (47,48), 
cell migration, formation of membrane protrusions (49), inva-
sion and proliferation (50).
Loss of CSMD1 expression resulted in hallmarks of trans-
formation including increased proliferation, migration and 
invasion. Our data support the proposed role of CSMD1 as a 
tumour suppressor. Potentially CSMD1 is involved in a signaling 
cascade regulating a wide range of cell processes. Future work 
will be aimed at dissecting the precise pathways involved.
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